Quarterly report pursuant to Section 13 or 15(d)

Segments (Tables)

v3.20.1
Segments (Tables)
3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Operations and Assets for Operating Segments and Geographic Information
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2020
 
2019
Revenue from services:
 
 
 
Pharmaceutical
$

 
$

Diagnostics
170,839

 
178,891

Corporate

 

 
$
170,839

 
$
178,891

Revenue from products:
 
 
 
Pharmaceutical
$
31,074

 
$
25,301

Diagnostics

 

Corporate

 

 
$
31,074

 
$
25,301

Revenue from transfer of intellectual property and other:
 
 
 
Pharmaceutical
$
9,553

 
$
18,259

Diagnostics

 

Corporate

 

 
$
9,553

 
$
18,259

Operating loss:
 
 
 
Pharmaceutical
$
(14,126
)
 
$
(29,477
)
Diagnostics
(18,133
)
 
(33,569
)
Corporate
(8,503
)
 
(12,272
)
 
$
(40,762
)
 
$
(75,318
)
Depreciation and amortization:
 
 
 
Pharmaceutical
$
7,121

 
$
7,526

Diagnostics
14,871

 
16,271

Corporate
60

 
19

 
$
22,052

 
$
23,816

Loss from investment in investees:
 
 
 
Pharmaceutical
$
(134
)
 
$
(1,854
)
Diagnostics

 

Corporate

 

 
$
(134
)
 
$
(1,854
)
Revenues:
 
 
 
United States
$
180,872

 
$
184,894

Ireland
11,901

 
20,534

Chile
10,850

 
7,865

Spain
4,156

 
4,418

Israel
1,707

 
3,116

Mexico
1,841

 
1,531

Other
139


93

 
$
211,466

 
$
222,451


(In thousands)
March 31,
2020
 
December 31,
2019
Assets:
 
 
 
Pharmaceutical
$
1,157,430

 
$
1,174,639

Diagnostics
1,026,880

 
1,035,112

Corporate
48,232

 
99,521

 
$
2,232,542

 
$
2,309,272

Goodwill:

 

Pharmaceutical
$
234,773

 
$
237,131

Diagnostics
434,809

 
434,809

Corporate

 

 
$
669,582

 
$
671,940